Safety, Tolerability and Pharmacokinetics of S 95010 After Single Escalating Intravenous Doses in Young Healthy Male Subjects. A Randomised, Doubleblind, Placebo-controlled, Monocentre, First-In-Human Study
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2018
At a glance
- Drugs MRG-110 (Primary)
- Indications Heart failure; Ischaemia
- Focus Adverse reactions; First in man
- Sponsors Servier
- 07 Nov 2018 According to a miRagen Therapeutics media release, the company expects to report the data from this trial in 2019.
- 20 Sep 2018 Planned End Date changed from 13 Jan 2020 to 24 Mar 2020.
- 20 Sep 2018 Planned primary completion date changed from 14 Jan 2019 to 25 Mar 2019.